Past Meeting| Keystone Symposia

This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).

Web Desc
Cancer Epigenetics joint with Transcriptional Regulation Organizer(s): Sharon Y.R. Dent, Jean-Pierre Issa and Peter A. Jones Date: February 04 - 09, 2014 Location: Santa Fe Community Convention Center, Santa Fe, NM, USA Sponsored by Astellas Pharma Inc., Celgene Corporation, Constellation Pharmaceuticals and Novartis Institutes for BioMedical Research Summary of Meeting: Epigenetic changes are now recognized to be as important to cancer formation as are gene mutations. Unlike mutations, however, epigenetic states can be altered, and epigenetic therapies hold promise as anti-cancer agents. For these approaches to succeed, we must understand how epigenetic states are created and maintained, and how they are altered in particular malignancies. This meeting will highlight large scale epigenome mapping efforts in normal cells, stem cells, and cancer cells, as well as genetic and biochemical studies focused on defining the mechanistic underpinning of these states. The meeting will bring together basic scientists studying the enzymes that govern epigenetic marks, particularly DNA methylation and histone post translational modifications, with translational and clinical researchers who are developing and implementing new epigenetic therapies. Opportunities for cross fertilization of ideas and interdisciplinary interactions will be further strengthened by joint keynote and plenary sessions with the concurrent meeting on Transcriptional Regulation. Scholarship Deadline: October 15 2013 Discounted Abstract Deadline: October 15 2013 Abstract Deadline: November 7 2013 Discounted Registration Deadline: December 4 2013 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: GlaxoSmithKline We gratefully acknowledge the generous grant for this conference provided by: National Cancer Institute (NCI) Grant No. 1R13CA181881-01 The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Cancer Epigenetics

joint with Transcriptional Regulation

Organizer(s): Sharon Y.R. Dent, Jean-Pierre Issa and Peter A. Jones

Date: February 04 - 09, 2014
Location: Santa Fe Community Convention Center, Santa Fe, NM, USA

Sponsored by Astellas Pharma Inc., Celgene Corporation, Constellation Pharmaceuticals and Novartis Institutes for BioMedical Research

Summary of Meeting:

Epigenetic changes are now recognized to be as important to cancer formation as are gene mutations. Unlike mutations, however, epigenetic states can be altered, and epigenetic therapies hold promise as anti-cancer agents. For these approaches to succeed, we must understand how epigenetic states are created and maintained, and how they are altered in particular malignancies. This meeting will highlight large scale epigenome mapping efforts in normal cells, stem cells, and cancer cells, as well as genetic and biochemical studies focused on defining the mechanistic underpinning of these states. The meeting will bring together basic scientists studying the enzymes that govern epigenetic marks, particularly DNA methylation and histone post translational modifications, with translational and clinical researchers who are developing and implementing new epigenetic therapies. Opportunities for cross fertilization of ideas and interdisciplinary interactions will be further strengthened by joint keynote and plenary sessions with the concurrent meeting on Transcriptional Regulation.

Scholarship Deadline: October 15 2013

Discounted Abstract Deadline: October 15 2013

Abstract Deadline: November 7 2013

Discounted Registration Deadline: December 4 2013

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

GlaxoSmithKline

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA181881-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found